臨床研究等提出・公開システム

A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma (AIRITY)

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice (AIRITY) (AIRITY)

De Prado Gomez Lucia

Sanofi-Aventis Recherche & Developpement

13 quai Jules Guesde 94400 Vitry-sur-Seine France

Lucia.DePradoGomez@sanofi.com

Sato Takashi

Syneos Health Japan K.K.

JP Tower, 2-7-2 Marunouchi, Chiyoda-ku, Tokyo

+81-3-6700-4700

Takashi.sato@syneoshealth.com

Recruiting

May. 27, 2026

Observational

non-randomized controlled trial

open(masking not used)

no treatment control/standard of care control

parallel assignment

treatment purpose

Part 1
Age 6 years and older at the time of signing the consent
Physician diagnosis of asthma for at least 12 months
Existing treatment with low, medium, or high dose ICS and other asthma controllers as reflected in GINA steps 2 to 5
Participant or legally authorized representative (where applicable) has provided consent

Part 2
Age 18 years and older at the time of signing the consent
Physician diagnosis of asthma for at least 12 months
Existing treatment with low or medium dose ICS and other asthma controllers as reflected in GINA steps 2 to 4
Participant or legally authorized representative (where applicable) has provided consent

Participants must meet the criteria for at least one of the cohorts below

Asthma Control Cohort
1 ACQ-5 greater than 1.5
2 ACQ-5 less than 1.5

Type 2 Biomarker Cohort
3 FeNO greater than or equal to 35 ppb and blood eosinophils greater than or equal to 300 cells per microliter
4 FeNO less than 35 ppb and blood eosinophils less than 300 cells per microliter

Current diagnosis of chronic obstructive pulmonary disease or congestive heart failure.
Participants with moderate/severe cognitive impairment.
Participants with moderate/severe cardiac disease.
Participants on immunosuppressive medication for a chronic condition.
Participation in other interventional and non-interventional clinical study (currently or in the past 3 months).

Both

Bronchial asthma

Bronchial asthma

D001249

Descriptive characterization of participants with asthma across severities based on physician and patient reported measures.
Patient and Physician Reported Outcomes

Physician perspectives
Participant perspectives
Descriptive characteristics of participants with elevated neutrophils and EOS by medication (including biologics) use and treatment outcomes

+81-3-5213-0028

May. 11, 2026

No

USA/Canada/France/Germany/Italy/Spain/China/Saudi Arabia/UAE